Platelet receptor levels during P2Y12 receptor blockade
Research type
Research Study
Full title
Comparing platelet receptor levels, signalling and functional responses in different combinations of anti-platelet therapy: PREdiCT study
IRAS ID
193007
Contact name
Muhammad Aungraheeta
Contact email
Sponsor organisation
University of Bristol
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Drugs such as aspirin and cloidogrel are widely used for the treatment or prevention of thrombosis in situations such as stroke and heart attack. It is already known that this group of drugs prevent thrombosis by reducing the activity of circulating blood platelets. However, new evidence from research laboratories suggest that the effects of anti-platelet drugs are more complex than initially thought, particularly just after new anti-platelet drugs are started or stopped. The purpose of this research is to explore at molecular levels, the precise changes in blood platelets that occur when anti-platelet drugs are started or stopped in patients with heart disease.The focus of investigation will be on levels of platelet receptors and signalling activity. Deeper understanding of the precise effect of anti-platelet drugs will help improve future clinical uncertainties such as choice of drug and timing of drug prescription.
REC name
South East Scotland REC 02
REC reference
16/SS/0034
Date of REC Opinion
27 Jan 2016
REC opinion
Favourable Opinion